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Previewsthis may not be the answer. Administering
higher doses of drug to patients is not an
option because of off-target effects and
toxicities. Due to its unique complexities,
perhaps it is time to look beyond RAF?
MEK inhibitors are showing promise in
the clinic while we all eagerly await clinical
data on inhibitors targeting ERK.REFERENCES
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In this issue of Cancer Cell, Be´guelin and colleagues highlight EZH2 as an essential regulator for B cell
activation and report an addiction of germinal center-derived neoplasms to EZH2 activity. This reversible
process is specifically targetable and hence presents high translational value for lymphoma therapy.The enhancer of zeste homolog 2 (EZH2)
is a SET domain containing methyl-
transferase catalyzing the methylation
of histone H3, forming the transcrip-
tional repressive epigenetic mark
H3K27me3. EZH2 is a subunit of a
multi-enzyme complex known as poly-
comb repressive complex 2 and is
involved in chromatin compaction and
gene repression. EZH2 is expressed in
undifferentiated stem and progenitor
cell types but predominantly silenced in
somatic cells. Despite its repressive
function through H3K27 tri-methylation,
it frequently co-localizes with the acti-
vating histone modification H3K4me3.
These bivalently marked genes present
minimal expression level in undiffer-
entiated cells, but upon differentiation
initiation, lose H3K27me3 and are tran-
scriptionally activated.Lymphogenesis represents a special
case wherein EZH2 is repressed in resting
naive B cells, but is highly upregulated in
primary lymphoid follicles during B cell
activation and germinal center (GC) for-
mation (Velichutina et al., 2010). Herein,
EZH2 defines a GC-specific repression
profile including silencing of cell cycle
checkpoints and differentiation factors.
This epigenetic setting allows rapid B
cell proliferation, an important step during
the maturation process in germinal cen-
ters. Consistently, EZH2 silencing results
in cell cycle arrest at G1/s transition
(Velichutina et al., 2010). In line with its
proliferation promoting function, EZH2
was shown to be highly expressed in
GC-derived lymphomas, such as diffuse
large B cell lymphomas (DLBCLs) (van
Kemenade et al., 2001). Moreover, muta-
tions in the SET domain, favoring theformation of trimethylated H3K27, have
recently been reported as frequent events
in DLBCL (Morin et al., 2011). EZH2
mutant tumor cells are almost exclusively
detected in the GC-derived subtype,
affecting about 20% of GCB-DLBCL
patients and suggesting a subtype-spe-
cific function of the alteration. Clinically,
mutant EZH2 can be specifically targeted
using small molecule inhibitors, such
as GSK126 (McCabe et al., 2012).
Following drug application, EZH2 mutant
lymphoma cells revealed reduced levels
of H3K27me3 and, most importantly, pre-
sented a highly impaired proliferative
potential in vitro and in mouse DLBCL
xenograft models.
Although there is clear evidence for
the contribution of EZH2 to B cell matura-
tion and neoplastic transformation in
GCB-DLBCLs, the underlying molecularl 23, May 13, 2013 ª2013 Elsevier Inc. 563
Figure 1. EZH2 Function Is an Important Component for B Cell Activation and
Lymphomagenesis
EZH2 is actively participating in the formation of germinal centers in lymphoid follicles; however, it is
repressed during later maturation steps. EZH2 hyperactivity (mutation or overexpression) further pro-
motes proliferation, resulting in hyperplasia. Additional oncogenic events are required for neoplastic
transformation, although germinal center-derived lymphomas remain addicted to EZH2 function. EZH2
inhibitors (e.g., GSK503) block hyperproliferation and transformation and are more effective against
lymphomas in combination with other specific therapies (e.g., BCL2 inhibition [BCL2i]). The presence of
EZH2 target gene hypermethylation in a subset of lymphomas suggests a potential positive implication
of DNA demethylating agents (e.g., 5-azacytidine [5-AZA]) in combinational therapies.
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fied. In this issue of Cancer Cell, Be´guelin
et al. (2013) performed a comprehensive
functional analysis of the role of EZH2 in
B cell biology and, in particular, during
the B cell maturation process in germinal
centers and associated lymphoma sub-
types. The authors provide solid evidence
that EZH2 expression is a crucial factor
for germinal center formation in the spleen
and that its repression in late GC B cells is
necessary to permit an exit from the
germinal center and allow subsequent
differentiation steps. Functionally, EZH2
establishes a de novo-formed chromatin
landscape, unique for GC B cells and
involving repressive and bivalent loci.
Mutant hyperactive EZH2 promotes the
formation of germinal centers harboring
highly proliferative B cells. Intriguingly,
Be´guelin et al. (2013) prove that, although
favoring a hyper-proliferative state of GC
B cells resulting in hyperplasia, mutant
EZH2 is not sufficient for cell transforma-
tion (Figure 1). They provide evidence
that additional oncogenic aberrations
(e.g., BCL2) are required to turn GC B
cells into diffuse large B cell lymphomas.
Important EZH2 downstream target
genes have been described for epithelial564 Cancer Cell 23, May 13, 2013 ª2013 Elstumors, but little is known about lym-
phomas. Be´guelin et al. (2013) identified
key EZH2 target genes in GC biology,
including CDKN1A, which is critical for
cell cycle checkpoint, and IRF4 and
PRDM1, transcription factors important
for GC exit. The latter switch from a
poised bivalent state to actively tran-
scribed regulators during normal B cell
maturation. CDKN1A and bivalent regula-
tors were hyper-repressed in EZH2
mutant DLBCL cells, suggesting that
transformed B cells are locked in their
immature state by effective repression
of anti-proliferative and differentiation-
inducing genes.
Clinically important, the authors pre-
sent evidence that GCB-DLBCLs are
addicted to the oncogenic function of
EZH2 independent of its mutational state,
as impaired enzyme activity abolished
tumorigenesis of mutant and wild-type
cancer cells. To specifically target
EZH2, the authors used a small-molecule
inhibitor (GSK503), highly reducing the
catalytic activity of mutant and wild-
type EZH2 and enabling broad poten-
tial application in GCB-DLBCLs. Herein,
the authors suggest GSK503 together
with BCL-2 inhibitors, as a combina-evier Inc.tional treatment, outperform single-drug
therapies in lymphoma models. Notably,
GSK503 activity was restricted to GCB-
DLBCL, without showing anticancer
effects on ABC-DLBCL, a lymphoma
subtype with repressed EZH2 derived
from late-stage GC B cells. This is consis-
tent with the observation that EZH2muta-
tions exclusively occur in GCB-DLBCLs,
but not in the ABC-subtype (Morin et al.,
2011).
Collectively, Be´guelin et al. (2013) now
prove that EZH2 is essential for the forma-
tion of germinal centers and that GC-
derived lymphoma subtypes are addicted
to the expression of wild-type or mutant
EZH2. Most importantly, they displayed
drug-induced reversibility of the transfor-
mation process with potential transla-
tional value for the clinic. Interestingly,
previous studies from the group pre-
sented evidence of EZH2 participation in
an epigenetic network involving DNA
methylation. Herein, they described a
gain of DNA methylation of EZH2 target
genes during lymphomagenesis (Velichu-
tina et al., 2010; De et al., 2013). Interest-
ingly, hypermethylation of polycomb
target genes (PcTGs) represents a fre-
quent event in oncogenesis reported for
leukemia and solid tumors (Schlesinger
et al., 2007; Sandoval et al., 2013). Func-
tionally, this is in contrast to the observa-
tion that H3K27me3 and DNA hyperme-
thylation are generally mutually exclusive
at gene promoters in a healthy context
(Statham et al., 2012). In this regard, two
scenarios can be considered when ex-
plaining the controversial epigenetic state
of PcTGs in cancer contexts: an epige-
netic switch from the repressive histone
mark H3K27me3 toward DNA hyperme-
thylation, herein reducing epigenetic
plasticity and locking the target genes in
a stable silent state. Alternatively, both
epigenetic repressors might co-localize
and thereby form a dual repressive state
at CpG islands and transcription start
sites in cancer (Statham et al., 2012). It
should be noted that de novoDNAmethyl-
ation of PcTGs mainly takes place at pre-
viously repressed and therefore silent
genes. Thus, the switch toward DNA
methylation or its co-localization with
H3K27me3 is likely to reinforce the repres-
sive state rather than induce major tran-
scriptional changes.
In GC-derived lymphomas, both
aforementioned scenarios might lock
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Previewsproliferation checkpoint genes, such as
CDKN1A, in their repressed state and,
thereby, cancer cells even tighter in their
undifferentiated phenotype. In this re-
gard, mutant EZH2 exhibits a similar
effect in GCB-DLBCL, with its hyperactiv-
ity increasing gene repression of B cell
maturation-related factors. In both aber-
ration types, a key position at the gate
toward B cell differentiation is held by
bivalent genes, whose hypermethylation
or hyper-repression with H3K27me3 fur-
ther blocks the B cells maturation pro-
cess and locks the cells in a germinal
center configuration. From a therapy
perspective, it would be of great interest
if GCB-DLBCL cases with a high degree
of epigenetic switches and hence
reduced reversibility were less sensitive
to EZH2 inhibitor treatment. Herein,
lymphoma patients with EZH2 hyper-
methylation phenotype might profit from
combinational therapies of EZH2 inhibi-
tors (McCabe et al., 2012) and DNA
demethylating agents (Herranz et al.,
2006) (Figure 1).Unlike in GCB-DLBCL, biological con-
sequences of PcTG hypermethylation
in other cancer types are not easy to
dissect. Here, PcTG silencing in cancer
types derived from tissue progenitor cells
might contribute to a transformation
process toward cancer stem cells by
effectively preventing cell differentiation.
Likewise, somatically-derived cancer
types might convert to a more undifferen-
tiated state with support of the formation
of a stem cell-like epigenetic setting.
Accordingly, in addition to DLBCL, other
tumor types might profit from therapeutic
strategies involving EZH2 inhibitors and
DNA demethylating agents.REFERENCES
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To preserve genome stability, BRCA1 must be recruited to sites of DNA damage, where BRCA1 facilitates
repair of double-strand DNA breaks (DSBs). In this issue of Cancer Cell, Li and Yu report that BRCA1 recruit-
ment involves a novel interaction between its partner protein BARD1 and poly(ADP-ribose) chains at the DSB.Germline mutations of BRCA1 are a pri-
mary cause of hereditary breast and
ovarian cancer. The central role of
BRCA1 in the cellular response to dou-
ble-strand DNA breaks (DSBs) is thought
to be a key aspect of its tumor suppres-
sion activity (Li and Greenberg, 2012).
The DSB response entails recruitment
of various signaling and repair factors,
including BRCA1, to nuclear sites of
damaged DNA. These factors selectively
accumulate at one or both of two cytolog-
ically distinct subcompartments: (1) the‘‘DSB end’’ itself and (2) the flanking
‘‘DSB chromatin’’ marked by gH2AX, a
phosphorylated form of the H2AX histone
variant (Bekker-Jensen et al., 2006). Of
note, BRCA1 can be recruited to both
subcompartments, suggesting that it
performs multiple, as yet undefined,
functions in DSB repair. Its localization
to DSB chromatin occurs through an
elaborate pathway that entails H2AX
phosphorylation, H2A polyubiquitination,
and ubiquitin-mediated recruitment of
the RAP80 complex (Li and Greenberg,2012). Ultimately, gH2AX-dependent
assembly of BRCA1 requires its direct
interaction with Abraxas, a polypeptide
within the RAP80 complex.
Early on, Celeste et al. (2003) reported
that BRCA1 recruitment to DSBs is a
kinetically biphasic process comprised
of an early gH2AX-independent stage
and a late gH2AX-dependent stage.
Subsequently, Mailand et al. (2007)
observed that BRCA1 localization to
DSB flanking chromatin, but not the DSB
end subcompartment, is ablated uponl 23, May 13, 2013 ª2013 Elsevier Inc. 565
